1. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
2. |
Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol, 2007, 292(3): C987-C995.
|
3. |
Lim JB, Chung HW. Serum ENA78/CXCL5, SDF-1/CXCL12, and their combinations as potential biomarkers for prediction of the presence and distant metastasis of primary gastric cancer. Cytokine, 2015, 73(1): 16-22.
|
4. |
Satomura H, Sasaki K, Nakajima M, et al. Can expression of CXCL12 and CXCR4 be used to predict survival of gastric cancer patients? Anticancer Res, 2014, 34(8): 4051-4057.
|
5. |
Chen G, Chen SM, Wang X, et al. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem, 2012, 287(15): 12132-12141.
|
6. |
Izumi D, Ishimoto T, Sugihara H, et al. Abstract 185: Cancer associated fibroblasts stimulates cancer cell invasion through CXCL12-CXCR4 signaling in gastric cancer. Cancer Res, 2014, 74 Suppl 19:185.
|
7. |
Izumi D, Ishimoto T, Miyake K, et al. CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin β1 clustering and invasiveness in gastric cancer. Int J Cancer, 2016, 138(5): 1207-1219.
|
8. |
Woo IS, Hong SH, Byun JH, et al. Circulating stromal cell derived factor-1α (SDF-1α) is predictive of distant metastasis in gastric carcinoma. Cancer Invest, 2008, 26(3): 256-261.
|
9. |
Park JY, Sung JY, Lee J, et al. Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer. Clin Res Hepatol Gastroenterol, 2016, 40(3): 357-365.
|
10. |
Iwasa S, Yanagawa T, Fan J, et al. Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res, 2009, 29(11): 4751-4758.
|
11. |
Shi A, Shi H, Dong L, et al. CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways. Scand J Gastroenterol, 2017, 52(6-7): 745-753.
|
12. |
Zhang Y, Zeng X, Lu H, et al. Association between Interleukin-8 -251A/T polymorphism and gastric cancer susceptibility: a meta-analysis based on 5 286 cases and 8 000 controls. Int J Clin Exp Med, 2015, 8(12): 22393-22402.
|
13. |
Ju D, Sun D, Xiu L, et al. Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med Oncol, 2012, 29(1): 91-99.
|
14. |
Madej-Michniewicz A, Budkowska M, Sałata D, et al. Evaluation of selected interleukins in patients with different gastric neoplasms: a preliminary report. Sci Rep, 2015, 5: 14382.
|
15. |
Li W, Zhou Y, Yang J, et al. Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through secretion of interleukin-8. J Exp Clin Cancer Res, 2015, 34: 52.
|
16. |
Shi J, Wei PK. Interleukin-8: A potent promoter of angiogenesis in gastric cancer. Oncol Lett, 2016, 11(2): 1043-1050.
|
17. |
Shi J, Li YJ, Yan B, et al. Interleukin-8: A potent promoter of human lymphatic endothelial cell growth in gastric cancer. Oncol Rep, 2015, 33(6): 2703-2710.
|
18. |
Kuai WX, Wang Q, Yang XZ, et al. Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol, 2012, 18(9): 979-985.
|
19. |
Jung JJ, Noh S, Jeung HC, et al. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Cancer Sci, 2010, 101(10): 2200-2206.
|
20. |
Cheng WL, Wang CS, Huang YH, et al. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol, 2011, 22(10): 2267-2276.
|
21. |
Xu J, Zhang C, He Y, et al. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer, 2012, 130(4): 787-797.
|
22. |
Wang Z, Wang Z, Li G, et al. CXCL1 from tumor-associated lymphatic endothelial cells drives gastric cancer cell into lymphatic system via activating integrin β1/FAK/AKT signaling. Cancer Lett, 2017, 385: 28-38.
|
23. |
Wei ZW, Xia GK, Wu Y, et al. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Lett, 2015, 359(2): 335-343.
|
24. |
Xing YN, Xu XY, Nie XC, et al. Role and clinicopathologic significance of CXC chemokine ligand 16 and chemokine (C-X-C motif) receptor 6 expression in gastric carcinomas. Hum Pathol, 2012, 43(12): 2299-2307.
|
25. |
Shen M, Hu P, Donskov F, et al. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One, 2014, 9(6): e98259.
|
26. |
Park JY, Park KH, Bang S, et al. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol, 2007, 133(11): 835-840.
|
27. |
Rajkumar T, Vijayalakshmi N, Gopal G, et al. Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int, 2010, 10: 45.
|
28. |
Gu H, Ni M, Guo X, et al. The functional polymorphism in monocyte chemoattractant protein-1 gene increases susceptibility to gastric cancer. Med Oncol, 2011, 28 Suppl 1: S280-S285.
|
29. |
Liu H, Shen Z, Wang X, et al. Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy. Tumour Biol, 2016, 37(3): 3285-3293.
|
30. |
Tas F, Karabulut S, Serilmez M, et al. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. Cancer Chemother Pharmacol, 2016, 77(1): 127-131.
|
31. |
Zhang J, Yan Y, Cui X, et al. CCL2 expression correlates with Snail expression and affects the prognosis of patients with gastric cancer. Pathol Res Pract, 2017, 213(3): 217-221.
|
32. |
Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett, 2008, 267(2): 204-215.
|
33. |
Kim J, Kim JW, Kim Y, et al. Differential association of RANTES -403 and IL-1B -1464 polymorphisms on histological subtypes in male Korean patients with gastric cancer. Tumour Biol, 2014, 35(4): 3765-3770.
|
34. |
Sugasawa H, Ichikura T, Kinoshita M, et al. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+cell-involved tumor elimination. Int J Cancer, 2008, 122(11): 2535-2541.
|
35. |
Wang T, Wei Y, Tian L, et al. C-C motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis. Int J Surg, 2016, 32: 136-142.
|
36. |
Wang G, Yu D, Tan W, et al. Genetic polymorphism in chemokine CCL22 and susceptibility to Helicobacter pylori infection-related gastric carcinoma. Cancer, 2009, 115(11): 2430-2437.
|
37. |
张伟国, 安伟德, 苗鑫, 等. 胃癌腹膜乳斑转移与趋化因子 CCL22 及受体 CC 类趋化因子受体-4 的关系. 中华实验外科杂志, 2013, 30(6): 1242-1244.
|
38. |
Wei Y, Wang T, Song H, et al. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy. J Surg Res, 2017, 211: 266-278.
|
39. |
Cao L, Hu X, Zhang J, et al. The role of the CCL22-CCR4 axis in the metastasis of gastric cancer cells into omental milky spots. J Transl Med, 2014, 12: 267.
|
40. |
Ohtani H, Nakayama T, Yoshie O. In situ expression of the CCL20-CCR6 axis in lymphocyte-rich gastric cancer and its potential role in the formation of lymphoid stroma. Pathol Int, 2011, 61(11): 645-651.
|
41. |
Han G, Wu D, Yang Y, et al. CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine, 2015, 76(2): 163-169.
|
42. |
Hwang TL, Lee LY, Wang CC, et al. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol, 2012, 18(11): 1249-1256.
|
43. |
Koç Ü, Çetinkaya E, Bostanci EB, et al. Diagnostic significance of serum eotaxin-1 level in gastric cancer patients. Dis Markers, 2013, 35(5): 363-367.
|
44. |
Hyakudomi M, Matsubara T, Hyakudomi R, et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol, 2008, 15(6): 1775-1782.
|
45. |
Wei LM, Cao S, Yu WD, et al. Overexpression of CX3CR1 is associated with cellular metastasis, proliferation and survival in gastric cancer. Oncol Rep, 2015, 33(2): 615-624.
|
46. |
Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta, 2013, 1836(2): 287-295.
|
47. |
Murakami T, Kawada K, Iwamoto M, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer, 2013, 132(2): 276-287.
|
48. |
Hu M, Li K, Maskey N, et al. Corrigendum to " Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer” (Hum Pathol 2015; 46: 1872-1880). Hum Pathol, 2016, 54: 203-204.
|
49. |
Zhou H, Wu J, Wang T, et al. CXCL10/CXCR3 axis promotes the invasion of gastric cancer via PI3K/AKT pathway-dependent MMPs production. Biomed Pharmacother, 2016, 82: 479-488.
|
50. |
Masuda T, Nakashima Y, Ando K, et al. Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. Anticancer Res, 2014, 34(11): 6397-6403.
|
51. |
Nikkhoo B, Jalili A, Fakhari S, et al. Nuclear pattern of CXCR4 expression is associated with a better overall survival in patients with gastric cancer. J Oncol, 2014, 2014: 808012.
|
52. |
Nikzaban M, Hakhamaneshi MS, Fakhari S, et al. The chemokine receptor CXCR4 is associated with the staging of gastric cancer. Adv Biomed Res, 2014, 3: 16.
|
53. |
Thomaidis T, Maderer A, Al-Batran SE, et al. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 2014, 14: 476.
|
54. |
罗君, 吴小翎. 抗 CXCR4 单克隆抗体 12G5 对胃癌细胞粘附与侵袭的影响. 重庆医科大学学报, 2008, 33(7): 817-820.
|
55. |
Iwanaga T, Iwasaki Y, Ohashi M, et al. Inhibitory effect of CXCR4 blockers on a CXCR4-expressing gastric cancer cell line in nude mice. Gan To Kagaku Ryoho, 2012, 39(12): 1788-1790.
|
56. |
Nambara S, Iguchi T, Oki E, et al. Overexpression of CXCR7 is a novel prognostic indicator in gastric cancer. Dig Surg, 2017, 34(4): 312-318.
|
57. |
Ma DM, Luo DX, Zhang J. SDF-1/CXCR7 axis regulates the proliferation, invasion, adhesion, and angiogenesis of gastric cancer cells. World J Surg Oncol, 2016, 14(1): 256.
|
58. |
Wang J, Hu W, Wu X, et al. CXCR1 promotes malignant behavior of gastric cancer cells in vitro and in vivo in AKT and ERK1/2 phosphorylation. Int J Oncol, 2016, 48(5): 2184-2196.
|
59. |
Cao Y, Liu H, Zhang H, et al. CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM Ⅱ and Ⅲ resectable gastric cancer patients. Oncotarget, 2017, 8(12): 20328-20339.
|
60. |
Li Z, Wang Y, Dong S, et al. Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro. Cytokine, 2014, 69(1): 6-13.
|
61. |
Li Y, Fu LX, Zhu WL, et al. Blockade of CXCR6 reduces invasive potential of gastric cancer cells through inhibition of AKT signaling. Int J Immunopathol Pharmacol, 2015, 28(2): 194-200.
|
62. |
Wang WN, Chen Y, Zhang YD, et al. The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer. Tumour Biol, 2013, 34(3): 1865-1871.
|
63. |
Ma H, Gao L, Li S, et al. CCR7 enhances TGF-β1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. Oncotarget, 2015, 6(27): 24348-24360.
|
64. |
Zhang J, Zhou Y, Yang Y. CCR7 pathway induces epithelial-mesenchymal transition through up-regulation of Snail signaling in gastric cancer. Med Oncol, 2015, 32(2): 467.
|
65. |
Zhou S, Shen Z, Wang Y, et al. CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One, 2013, 8(9): e74430.
|
66. |
Lee JH, Cho YS, Lee JY, et al. The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer. Ann Surg, 2009, 249(6): 933-941.
|
67. |
Yang YM, Feng AL, Zhou CJ, et al. Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor-induced immunosuppression. Cancer Sci, 2011, 102(7): 1264-1271.
|
68. |
Yang Y, Du L, Yang X, et al. Aberrant CCR4 expression is involved in tumor invasion of lymph node-negative human gastric cancer. PLoS One, 2015, 10(3): e0120059.
|
69. |
Cao Z, Xu X, Luo X, et al. Role of RANTES and its receptor in gastric cancer metastasis. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(3): 342-347.
|
70. |
Zhang XG, Song BT, Liu FJ, et al. CCR6 overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer. Clin Transl Oncol, 2016, 18(7): 700-707.
|